Mankind Pharma Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Low debt relative to equity (D/E 0.4x)
Concerns
Today's Price Action
The stock trades at ₹2,327.9 with no change on the day. Trading volume stands at 1,22,365 shares, matching the 20‑day average, indicating that participation levels are typical for this stock and that there is no unusual surge or drop in interest today.
Valuation Snapshot
Mankind Pharma Limited’s trailing P/E ratio is 46.2, considerably higher than the implied sector benchmark of zero (the sector P/E is currently unavailable). The company posts a return on equity of 13.1%, suggesting decent profitability relative to its equity base.
Key Levels to Watch
The 52‑week range stretches from a low of ₹1,910 to a high of ₹2,674, placing the current price roughly midway and comfortably above the lower bound. Open‑interest data (not provided) would typically be examined for near‑term support or resistance, but the existing price sits nearer the upper half of its annual band.
Chart Pattern
In the last ten trading sessions the daily chart displayed a Bearish Harami (two sessions ago) followed by a Bullish Engulfing pattern three sessions ago, and a Hanging Man five sessions ago. These formations are observed on the daily timeframe and reflect short‑term indecision and potential reversal points within the recent price action.
Data Summary
Key metrics include a market‑capitalisation figure listed as ₹0 Cr, a P/B ratio of 0, and a P/E of 46.2. The share’s price oscillates within a ₹1,910‑₹2,674 band, while recent candlestick patterns suggest the market is testing both bullish and bearish thresholds.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MANKIND · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 76.50% | 74.88% | 74.87% | 74.87% | 72.71% | 72.70% |
| FII | 6.74% | 9.87% | 11.58% | 12.37% | 13.34% | 12.92% |
| DII | 9.78% | 11.14% | 9.94% | 9.91% | 11.05% | 11.47% |
| Public | 6.97% | 4.10% | 3.61% | 2.86% | 2.89% | 2.89% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
To consider and approve the financial results for the period ended March 31, 2026
Interim Dividend - Re 1 Per Share
Latest News
All newsMankind Pharma reports Q1 FY26 financial results
*Mankind Pharma reports Q1 FY26 financial results.* The company has announced its financial performance for the quarter ended June 30, 2026. Results include key metrics such as **revenue**, **profit after tax**, and **EPS**, which will influence investor sentiment. The full report is available in the NSE corporate filing. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Mankind Pharma inks exclusive insulin licensing deal
*Mankind Pharma inks exclusive insulin licensing deal* for Insulin Degludec and its combination in India. The agreement boosts its diabetes portfolio with potential for future revenue growth. No financial terms were disclosed. This strategic move enhances its presence in the chronic care segment. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Mankind Pharma to host analyst and investor meet
*Mankind Pharma to host an analyst and institutional investor meet.* The event is aimed at providing updates on company performance and strategy. Specific financial figures or guidance were not disclosed in the filing. Investors may expect insights into recent trends and future outlook. 📊 *STOCKS:* MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Mankind Pharma hosts analyst investor call
*Mankind Pharma hosts analyst and institutional investor meet.* The company provided updates on recent business performance and strategic outlook. No major financial revisions or surprises were announced. The session focused on Q4 results and future guidance. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Mankind Pharma shares to face block trading
Mankind Pharma has published a newspaper notice regarding a block deal. The transaction involves a portion of promoter-held shares. No financial details disclosed, likely routine stake restructuring. 📊 *STOCKS:* MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #blockdeal
Mankind Pharma shares may see volatility on newspaper publication
*Mankind Pharma shares may see volatility on newspaper publication.* The company filed a copy of a newspaper publication with the NSE, likely related to a regulatory or corporate disclosure. Such filings are routine and typically do not carry material business implications. Impact on trading is expected to be minimal. 📊 *STOCKS:* MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Mankind Pharma announces general corporate updates
*Mankind Pharma announces general corporate updates.* No specific financial or operational details disclosed. The filing does not reveal any major strategic moves or results. Traders may await further clarity. 📊 *STOCKS:* MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporateupdate
Mankind Pharma releases pledge on Bharat Serums shares
*Mankind Pharma releases pledge on Bharat Serums shares after revising NCD security cover.* The move follows a restructuring of debt security, reducing collateral requirements. **No financial figures** were disclosed, suggesting minimal immediate market impact. This eases investor concerns around promoter pledging. 📊 *STOCKS:* MANKIND, BSV | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pledge
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.6K Cr 3.5% | ₹3.7K Cr 3.6% | ₹3.6K Cr 15.9% | ₹3.1K Cr 3.8% | ₹3.2K Cr 4.5% | ₹3.1K Cr 6.7% | ₹2.9K Cr 18.4% | ₹2.4K Cr |
| Op. Profit | ₹919 Cr 0.2% | ₹921 Cr 8.7% | ₹847 Cr 24.0% | ₹683 Cr 16.3% | ₹816 Cr 3.7% | ₹847 Cr 26.0% | ₹672 Cr 14.7% | ₹586 Cr |
| OPM | 26.0% 4.0% | 25.0% 4.2% | 24.0% 9.1% | 22.0% 15.4% | 26.0% 7.1% | 28.0% 21.7% | 23.0% 4.2% | 24.0% |
| Net Profit | ₹414 Cr 20.4% | ₹520 Cr 16.9% | ₹445 Cr 4.7% | ₹425 Cr 10.4% | ₹385 Cr 41.6% | ₹659 Cr 21.4% | ₹543 Cr 13.8% | ₹477 Cr |
| EPS (₹) | 9.9 20.1% | 12.39 16.7% | 10.62 4.1% | 10.2 10.6% | 9.22 43.5% | 16.31 21.8% | 13.39 13.9% | 11.76 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14.3K Cr 17.0% | ₹12.2K Cr 19.0% | ₹10.3K Cr 17.3% | ₹8.7K Cr 12.4% | ₹7.8K Cr 25.2% | ₹6.2K Cr 6.0% | ₹5.9K Cr 75.9% | ₹3.3K Cr |
| Expenses | ₹10.7K Cr 16.0% | ₹9.2K Cr 18.6% | ₹7.7K Cr 13.1% | ₹6.8K Cr 18.3% | ₹5.8K Cr 26.9% | ₹4.6K Cr 3.1% | ₹4.4K Cr 61.1% | ₹2.7K Cr |
| Op. Profit | ₹3.6K Cr 19.8% | ₹3.0K Cr 20.2% | ₹2.5K Cr 32.3% | ₹1.9K Cr 4.5% | ₹2.0K Cr 20.7% | ₹1.6K Cr 14.7% | ₹1.4K Cr 145.4% | ₹586 Cr |
| OPM | 25.0% 0.0% | 25.0% 0.0% | 25.0% 13.6% | 22.0% 15.4% | 26.0% 3.7% | 27.0% 8.0% | 25.0% 38.9% | 18.0% |
| Other Income | ₹238 Cr 56.6% | ₹548 Cr 85.8% | ₹295 Cr 109.2% | ₹141 Cr 32.9% | ₹210 Cr 14.8% | ₹183 Cr 50.0% | ₹122 Cr 60.5% | ₹76 Cr |
| Interest | ₹644 Cr 49.1% | ₹432 Cr 1170.6% | ₹34 Cr 26.1% | ₹46 Cr 23.3% | ₹60 Cr 185.7% | ₹21 Cr 8.7% | ₹23 Cr 1050.0% | ₹2 Cr |
| Depreciation | ₹886 Cr 42.7% | ₹621 Cr 64.3% | ₹378 Cr 16.0% | ₹326 Cr 95.2% | ₹167 Cr 40.3% | ₹119 Cr 20.2% | ₹99 Cr 153.8% | ₹39 Cr |
| PBT | ₹2.3K Cr 7.5% | ₹2.5K Cr 5.1% | ₹2.4K Cr 43.6% | ₹1.7K Cr 15.4% | ₹2.0K Cr 16.7% | ₹1.7K Cr 17.7% | ₹1.4K Cr 131.6% | ₹621 Cr |
| Tax % | 17.0% 15.0% | 20.0% 5.3% | 19.0% 13.6% | 22.0% 15.4% | 26.0% 8.3% | 24.0% 11.1% | 27.0% 6.9% | 29.0% |
| Net Profit | ₹1.9K Cr 3.6% | ₹2.0K Cr 3.6% | ₹1.9K Cr 48.2% | ₹1.3K Cr 9.8% | ₹1.5K Cr 12.4% | ₹1.3K Cr 22.4% | ₹1.1K Cr 137.3% | ₹445 Cr |
| EPS (₹) | 46.34 4.0% | 48.26 1.1% | 47.75 49.2% | 32 10.6% | 35.78 13.3% | 31.59 22.8% | 25.72 88.3% | 219.33 |
| Div Payout | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% 100.0% | 24.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
Liabilities | |||||||||
| Equity Capital | ₹41 Cr 0.0% | ₹41 Cr 0.0% | ₹41 Cr 2.5% | ₹40 Cr 0.0% | ₹40 Cr 0.0% | ₹40 Cr 0.0% | ₹40 Cr 0.0% | ₹40 Cr 100.0% | ₹20 Cr |
| Reserves | ₹16.3K Cr 6.7% | ₹15.2K Cr 6.7% | ₹14.3K Cr 53.3% | ₹9.3K Cr 26.1% | ₹7.4K Cr 20.9% | ₹6.1K Cr 30.6% | ₹4.7K Cr 35.9% | ₹3.4K Cr 69.3% | ₹2.0K Cr |
| Borrowings | ₹6.3K Cr 24.6% | ₹8.4K Cr 1.7% | ₹8.5K Cr 4011.6% | ₹207 Cr 21.8% | ₹170 Cr 80.5% | ₹873 Cr 262.2% | ₹241 Cr 84.0% | ₹131 Cr | ₹0 Cr |
| Other Liabilities | ₹5.1K Cr 0.3% | ₹5.2K Cr 7.3% | ₹4.8K Cr 107.9% | ₹2.3K Cr 11.2% | ₹2.1K Cr 0.0% | ₹2.1K Cr 48.9% | ₹1.4K Cr 3.6% | ₹1.4K Cr 49.7% | ₹968 Cr |
| Total Liabilities | ₹27.8K Cr 3.7% | ₹28.8K Cr 4.2% | ₹27.7K Cr 132.7% | ₹11.9K Cr 22.7% | ₹9.7K Cr 6.3% | ₹9.1K Cr 43.2% | ₹6.4K Cr 25.6% | ₹5.1K Cr 67.6% | ₹3.0K Cr |
Assets | |||||||||
| Fixed Assets | ₹18.6K Cr 3.3% | ₹19.3K Cr 1.4% | ₹19.0K Cr 318.2% | ₹4.5K Cr 6.9% | ₹4.3K Cr 18.5% | ₹3.6K Cr 115.6% | ₹1.7K Cr 4.0% | ₹1.6K Cr 406.3% | ₹316 Cr |
| CWIP | ₹1.1K Cr 186.3% | ₹394 Cr 52.3% | ₹826 Cr 192.9% | ₹282 Cr 48.7% | ₹550 Cr 21.5% | ₹701 Cr 88.4% | ₹372 Cr 17.4% | ₹317 Cr 574.5% | ₹47 Cr |
| Investments | ₹2.0K Cr 32.6% | ₹2.9K Cr 44.3% | ₹2.0K Cr 20.5% | ₹2.6K Cr 90.8% | ₹1.3K Cr 21.4% | ₹1.1K Cr 26.7% | ₹1.5K Cr 82.4% | ₹829 Cr 13.6% | ₹959 Cr |
| Other Assets | ₹6.0K Cr 3.0% | ₹6.2K Cr 7.4% | ₹5.8K Cr 28.8% | ₹4.5K Cr 26.9% | ₹3.5K Cr 4.6% | ₹3.7K Cr 31.9% | ₹2.8K Cr 21.2% | ₹2.3K Cr 36.4% | ₹1.7K Cr |
| Total Assets | ₹27.8K Cr 3.7% | ₹28.8K Cr 4.2% | ₹27.7K Cr 132.7% | ₹11.9K Cr 22.7% | ₹9.7K Cr 6.3% | ₹9.1K Cr 43.2% | ₹6.4K Cr 25.6% | ₹5.1K Cr 67.6% | ₹3.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹3.1K Cr 29.3% | ₹2.4K Cr 12.1% | ₹2.2K Cr 18.7% | ₹1.8K Cr 97.1% | ₹920 Cr 19.1% | ₹1.1K Cr 6.3% | ₹1.1K Cr | — |
| Investing CF | ₹-181 Cr 98.6% | ₹-12.6K Cr 506.6% | ₹-2.1K Cr 97.8% | ₹-1.1K Cr 23.2% | ₹-1.4K Cr 12.0% | ₹-1.2K Cr 180.3% | ₹-436 Cr | — |
| Financing CF | ₹-3.0K Cr 128.9% | ₹10.2K Cr 204560.0% | ₹5 Cr 100.7% | ₹-740 Cr 222.3% | ₹605 Cr 7662.5% | ₹-8 Cr 98.5% | ₹-531 Cr | — |
| Net Cash Flow | ₹-12 Cr 154.5% | ₹22 Cr 71.4% | ₹77 Cr 250.0% | ₹22 Cr 85.9% | ₹156 Cr 269.6% | ₹-92 Cr 189.3% | ₹103 Cr | — |
| Free Cash Flow | ₹2.4K Cr 26.0% | ₹1.9K Cr 7.0% | ₹1.8K Cr 79.4% | ₹987 Cr 169.4% | ₹-1.4K Cr 272.3% | ₹826 Cr 3.2% | ₹853 Cr | — |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44d 4.3% | 46d 53.3% | 30d 25.0% | 24d 33.3% | 18d 5.3% | 19d 42.4% | 33d 50.0% | 22d |
| Inventory Days | 193d 11.9% | 219d 21.7% | 180d 4.3% | 188d 29.1% | 265d 9.1% | 243d 38.9% | 175d 5.4% | 166d |
| Days Payable | 121d 1.7% | 119d 32.2% | 90d 28.6% | 126d 22.2% | 162d 18.2% | 137d 5.5% | 145d 104.2% | 71d |
| Cash Conv. Cycle | 117d 19.9% | 146d 21.7% | 120d 39.5% | 86d 28.9% | 121d 3.2% | 125d 98.4% | 63d 46.2% | 117d |
| Working Capital Days | -40d 42.9% | -28d 152.8% | 53d 35.9% | 39d 62.5% | 24d 25.0% | 32d 6.7% | 30d 46.4% | 56d |
| ROCE | 14.0% 17.6% | 17.0% 34.6% | 26.0% 18.2% | 22.0% 31.3% | 32.0% 13.5% | 37.0% | — | — |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Mankind Pharma Limited
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
HealthcarePharmaceuticals & Biotechnology